Australia’s regulatory agency rejected Biogen and Eisai’s Alzheimer’s drug Leqembi, noting that the drug's efficacy doesn't ...

In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...

BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of ...

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...

The Therapeutic Goods Administration (TGA) has made the decision not to register lecanemab (LEQEMBI) for the treatment of ...

A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...

Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.

People sense millisecond shifts in odor as quickly as they might spot a change in color, new research shows. The study ...

Enrollment in a 2025 Medicare plan opened for beneficiaries today. News outlets focus on an array of changes that could lead to "benefit disruption" that consumers should know about, in particular ...

New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...

A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...